VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialisation of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The NKF team was led by Capital Markets partners Thomas Brönnimann and Philippe Weber, working with senior associate Deirdre Ni Annrachain (Capital Markets), partner Markus Kronauer and associate Vanessa Witschi (both Tax).